The NHS advises against routine prostate cancer screening in men of any age because the harms outweigh the benefits. This also applies to men at higher risk, with the exception of those with known BRCA1 or BRCA2 genetic mutations. Prostate-specific antigen (PSA) screening cannot reliably identify patients with clinically significant prostate cancer. It leads to unnecessary testing, imaging and biopsies in healthy, asymptomatic men. Magnetic resonance imaging (MRI) as a pretest can reduce the number of biopsies and detect low-grade cancers, but increases cost and complexity. Prostate cancer is heterogeneous; aggressive forms metastasize and cause death, but most are grade 1 with little or no risk of progression or metastasis. The National Screening Committee (NSC) reached these conclusions based on the available evidence.